查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1870844

診斷試劑市場按產品類型、最終用戶和應用分類 - 全球預測 2025-2032

Diagnostic Substances Market by Product Type, End-User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，診斷材料市場規模將達到 2,984.7 億美元，複合年成長率為 6.64%。

關鍵市場統計數據
基準年 2024 1783.6億美元
預計年份：2025年 1895.3億美元
預測年份 2032 2984.7億美元
複合年成長率 (%) 6.64%

從技術創新、臨床效用預期、策略供應鏈需求三個角度分析當前的診斷環境。

在科學創新、臨床實踐變革和監管力度加大的推動下，診斷產業正經歷快速變革時期。分子診斷、影像技術和高通量檢測技術的進步正在重塑臨床醫生、實驗室和研究機構識別和監測疾病的方式。同時，支付方和採購團隊也越來越重視臨床效用和營運效率的證據，要求製造商和服務提供者證明其產品除了分析效能之外，還具有明確的價值提案。

科學突破、數位整合、不斷變化的監管環境以及支付方的需求如何重塑競爭格局和價值創造

科學突破、數位整合以及相關人員期望的轉變正在改變醫療格局。精準的分子工具和先進的成像系統能夠實現疾病的早期特異性檢測，從而推動了對配套試劑盒、檢測方法和特殊試劑的需求，以支援標靶工作流程。同時，數位健康平台和實驗室資訊系統（LIS）正在改善數據收集和分析，使醫療服務提供者能夠利用診斷結果為決策和社區醫療政策提供支援。

評估近期美國關稅政策對診斷供應鏈和採購韌性的營運和策略影響

美國實施的關稅政策為營運全球供應鏈並服務國內終端用戶的公司帶來了新的挑戰。某些類型的檢測設備、試劑和進口零件關稅的提高增加了到岸成本，促使買家重新評估籌資策略。為此，許多供應商開始改變採購方式，包括供應商多元化、增加區域庫存緩衝以及重新談判供應商契約，以在維持服務水準的同時保護利潤率。

透過市場分析，利用跨產品類型、最終用戶環境以及臨床和研究應用的多層次細分，識別策略轉折點。

精細化的細分框架揭示了產品類型、最終用戶和應用領域中的競爭優勢和未滿足的需求。在檢驗產品類型差異時，儀器可細分為分析儀器、影像設備和分子診斷儀器，其中分子診斷儀器包括次世代定序平台和PCR儀器。試劑盒和檢測方法包括ELISA試劑盒、橫向流動化驗、PCR試劑盒和快速檢測套組，每種試劑盒都針對從集中式到分散式檢查的不同應用情境。試劑構成一個獨立的支柱，包括抗體試劑、抗原試劑、酵素、核酸試劑和重組蛋白，這些試劑共同支撐著檢測的性能和可重複性。

比較美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和商業化需求，將影響產品的採用和監管應對措施。

區域趨勢持續影響美洲、歐洲、中東和非洲以及亞太地區的需求模式、監管方式和投資重點。在美洲，一體化醫療體系和大型實驗室網路催生了對可擴展設備、綜合檢測方案以及支持報銷的基於價值的證據的需求。該地區也高度重視公共衛生緊急準備，這影響快速檢測套組和高通量分析儀的採購。

主要企業如何協調技術、製造和服務方面的投資，以確保永續的商業性優勢和機構夥伴關係

診斷生態系中的企業正圍繞著技術深度、上游試劑管理和以服務為導向的商業化這三大核心構面調整其策略。領先的儀器製造商正投資於平台互通性、軟體賦能的診斷技術，並拓展服務組合，以確保與客戶建立長期合作關係。同時，專業試劑供應商則專注於高品質的原料和生產的一致性，因為他們意識到，檢測結果的可重複性正受到監管機構和臨床用戶的日益嚴格的審查。

為行業領導者提供切實可行的策略舉措，以增強韌性、加快普及速度並在診斷領域創造永續的商業性差異化優勢

產業領導者應優先採取重點行動，以應對不確定性並抓住策略機會。首先，投資增強製造韌性和供應商多元化，將降低受貿易政策波動和零件短缺的影響，同時保障臨床客戶的持續供應。其次，加強監管和臨床證據建立能力，將加快在複雜司法管轄區的市場進入，並為支付方提供製定醫療決策所需的數據。第三，將數位化功能（從連接和分析到遠端監測）嵌入儀器和檢測方法中，可以創造持續的收入來源並提高客戶維繫。

綜合調查方法結合了基礎研究、監管分析和價值鏈分析，以確保獲得嚴謹且檢驗的洞見。

本分析整合了第一手和第二手研究資料，以提供關於診斷試劑的全面觀點。第一手研究資料包括對實驗室主任、採購人員、監管專家和產品開發負責人進行的結構化訪談，從而獲得關於應用促進因素、營運挑戰和採購重點的實地洞察。這些質性研究資料與二級資訊來源（包括同儕審查文獻、監管指導文件和公司備案文件）進行三角驗證，以確保事實的嚴謹性和背景的深度。

最終整合凸顯了技術卓越、法規遵循、實際效用之間的協調一致，而這正是未來成功的關鍵因素。

診斷技術處於技術創新與臨床需求的交會點，其近期發展前景將取決於企業如何將產品功能與實際臨床和營運需求有效結合。對臨床效用、供應鏈韌性和合規性的日益重視提高了新參與企業的門檻，同時也獎勵了那些能夠展現端到端可靠性的企業。同時，數位化和整合服務模式正在創造新的觸點，以建立超越簡單交易的長期客戶參與。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 基於 CRISPR 技術的傳染病檢查診斷劑獲得監管部門核准數量激增
  • 擴大照護現場
  • 將人工智慧影像分析技術整合到免疫組織化學診斷中，以改善癌症亞型分類。
  • 加強診斷劑供應商與遠端醫療平台之間的合作，以實現遠端樣本分析
  • 在液態生物檢體診斷中採用次世代定序技術進行癌症早期檢測
  • 開發用於環境友善照護現場診斷檢測的可生物分解微流體晶片
  • 多重免疫檢測在自體免疫疾病監測中的應用日益廣泛，尤其針對細胞激素譜。
  • 奈米抗體試劑的出現提高了體外免疫檢測的靈敏度
  • 精準醫療中，與標靶癌症治療相關的伴隨診斷需求迅速成長。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：診斷試劑市場（依產品類型分類）

  • 裝置
    • 分析器
    • 影像設備
    • 分子診斷設備
      • 次世代定序
      • PCR裝置
  • 試劑盒和檢測
    • ELISA試劑盒
    • 橫向流動化驗
    • PCR試劑盒
    • 快速檢測套組
  • 試劑
    • 抗體試劑
    • 抗原試劑
    • 酵素
    • 核酸試劑
    • 重組蛋白

9. 按最終用戶分類的診斷材料市場

  • 診斷實驗室
  • 法醫科學研究所
  • 醫院和診所
  • 就地檢驗設施
  • 研究和學術機構

第10章 按應用分類的診斷材料市場

  • 臨床診斷
    • 心臟病學
    • 內分泌學
    • 感染疾病
    • 神經病學
    • 腫瘤學
  • 法醫學
    • 血液樣本檢測
    • DNA分析
    • 毒理學
  • 研究
    • 藥物發現
    • 基因組研究
    • 蛋白質體學調查

第11章 各地區診斷材料市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：按組別分類的診斷材料市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國診斷試劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Asuragen, Inc. by Bio-Techne Corporation
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • bioLytical Laboratories
    • bioMerieux SA
    • Cepheid by Danaher Corporation
    • DiaSorin SpA
    • Enzo Biochem, Inc.
    • Hitachi Ltd.
    • Hoffmann-La Roche AG
    • Hologic Inc.
    • HyTest Ltd.
    • Illumina Inc.
    • Merck KGaA
    • OraSure Technologies, Inc.
    • Ortho Clinical Diagnostics
    • Qiagen NV
    • Quidel Corporation
    • Randox Laboratories Ltd.
    • Sekisui Diagnostics, LLC
    • Siemens AG
    • Sysmex Corporation by TOA Corporation
    • Thermo Fisher Scientific Inc.
Product Code: MRR-1A1A064C040C

The Diagnostic Substances Market is projected to grow by USD 298.47 billion at a CAGR of 6.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 178.36 billion
Estimated Year [2025] USD 189.53 billion
Forecast Year [2032] USD 298.47 billion
CAGR (%) 6.64%

Framing the current diagnostic substances environment by examining technological innovation, clinical utility expectations, and strategic supply chain imperatives

The diagnostic substances arena is undergoing a period of rapid evolution driven by scientific innovation, shifting clinical practice, and heightened regulatory scrutiny. Technological advances in molecular diagnostics, imaging modalities, and high-throughput assay formats are reshaping how clinicians, laboratories, and research organizations identify and monitor disease. At the same time, payers and procurement teams are placing greater emphasis on evidence of clinical utility and operational efficiency, which is prompting manufacturers and service providers to demonstrate clear value propositions beyond analytical performance.

Across laboratory networks and point-of-care settings, operational resilience and supply chain continuity have ascended as strategic priorities. Stakeholders are balancing the imperative to adopt cutting-edge instruments and assays with the need to ensure reproducibility, affordability, and regulatory compliance. Consequently, partnerships among instrument makers, reagent suppliers, and clinical networks are becoming more integrated, with cross-functional collaborations focused on workflow optimization, data interoperability, and lifecycle support. Taken together, these dynamics are recalibrating investment decisions and competitive positioning in diagnostic substances, creating new opportunities for organizations that can translate technical differentiation into measurable clinical and economic outcomes.

How scientific breakthroughs, digital integration, regulatory evolution, and payer demands are collectively reshaping competitive dynamics and value creation

The landscape is being transformed by a confluence of scientific breakthroughs, digital integration, and shifting stakeholder expectations. Precision-focused molecular tools and advanced imaging systems are enabling earlier and more specific detection of disease, which in turn is driving demand for complementary kits, assays, and specialized reagents that can support targeted workflows. Simultaneously, digital health platforms and laboratory information systems are improving data capture and analytics, enabling providers to harness diagnostic outputs for decision support and population health initiatives.

Regulatory frameworks are also evolving to accommodate novel modalities and accelerate review pathways for high-impact diagnostics, which creates both opportunities and compliance challenges for manufacturers. Payers are increasingly requiring evidence of clinical and economic benefit, prompting firms to invest in real-world evidence generation and post-market surveillance. Finally, market participants are responding to procurement pressures by redesigning service models and aftersales support, prioritizing total cost of ownership and uptime guarantees. Collectively, these trends are shifting competitive dynamics toward vertically integrated solutions and strategic alliances that can deliver end-to-end value to laboratories, hospitals, and research institutions.

Assessing the operational and strategic ramifications of recent United States tariff policies on diagnostic supply chains and procurement resilience

Tariff actions implemented in the United States have introduced new layers of complexity for firms operating global supply chains and servicing domestic end-users. Increased duties on specific classes of laboratory instruments, reagents, and imported components have elevated landed costs and prompted buyers to reassess sourcing strategies. In response, many suppliers have initiated changes to procurement, including diversifying supplier bases, increasing regional inventory buffers, and renegotiating supplier contracts to protect margins while preserving service levels.

These shifts have also accelerated conversations around onshoring and nearshoring of critical manufacturing and subassembly capabilities. Manufacturers and contract providers are weighing the trade-offs between higher fixed investments for domestic capacity and the resilience benefits that come from reduced exposure to cross-border tariff volatility. At the same time, downstream stakeholders-diagnostic laboratories, hospitals, and point-of-care providers-are adapting procurement protocols to account for longer lead times and potential component substitution. This environment reinforces the importance of transparent supplier communication, contractual flexibility, and scenario planning to mitigate the cumulative operational impacts of tariff-induced cost pressures while maintaining clinical continuity.

Deconstructing the market through layered segmentation across product types, end-user settings, and clinical and research applications to identify strategic inflection points

A nuanced segmentation framework reveals where competitive advantages and unmet needs are concentrated across product types, end-users, and applications. When examining product type distinctions, instruments are subdivided into analyzers, imaging equipment, and molecular diagnostic instruments, with the latter category encompassing next-generation sequencing platforms and PCR machines. Kits and assays include ELISA kits, lateral flow assays, PCR kits, and rapid test kits, each serving distinct use cases from centralized laboratories to decentralized testing. Reagents form a separate pillar and comprise antibody reagents, antigen reagents, enzymes, nucleic acid reagents, and recombinant proteins, which collectively underpin assay performance and reproducibility.

Turning to end-user segmentation, diagnostic laboratories and forensic laboratories demand high-throughput, validated solutions with robust quality management and chain-of-custody capabilities, whereas hospitals and clinics prioritize integrated workflows and clinician-facing usability. Point-of-care testing facilities emphasize portability, speed, and simplicity, and research and academic institutes focus on versatility and advanced methodological support. Regarding applications, clinical diagnostics spans cardiology, endocrinology, infectious diseases, neurology, and oncology, each with unique biomarker requirements and regulatory pathways. Forensic applications center on blood sample testing, DNA analysis, and toxicology, while research applications include drug discovery, genomics research, and proteomics research. This layered segmentation highlights where product innovation, regulatory navigation, and tailored go-to-market strategies can yield the greatest returns for suppliers and service providers.

Comparative regional dynamics and commercialization imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine adoption and regulatory engagement

Regional dynamics continue to shape demand patterns, regulatory approaches, and investment priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated healthcare systems and large laboratory networks create demand for scalable instrumentation, integrated assay portfolios, and value-based evidence that supports reimbursement. The region also emphasizes public health preparedness, which influences procurement of rapid test kits and high-throughput analyzers.

Europe, Middle East & Africa features a mosaic of regulatory regimes and reimbursement landscapes, where harmonization initiatives coexist with national-level variability. This environment elevates the importance of local regulatory expertise, adaptable product configurations, and partnerships that can navigate fragmented reimbursement pathways. Asia-Pacific is characterized by rapid adoption of molecular diagnostics and point-of-care modalities, driven by large patient volumes, robust research activity, and government-led health modernization programs. Across regions, manufacturers are balancing global platform strategies with localized commercialization tactics to address distinct clinical priorities, regulatory hurdles, and infrastructure constraints.

How leading companies are aligning technological, manufacturing, and service investments to secure durable commercial advantages and institutional partnerships

Company strategies in the diagnostic substances ecosystem are differentiating along axes of technological depth, upstream reagent control, and service-oriented commercialization. Leading instrument manufacturers are investing in platform interoperability, software-enabled diagnostics, and expanded service portfolios to lock in long-term customer relationships. At the same time, specialized reagent providers are focusing on high-quality raw materials and manufacturing consistency, recognizing that reproducibility of assays is increasingly scrutinized by regulators and clinical users.

Strategic partnerships and M&A activity continue to be tools for filling capability gaps, whether to add molecular expertise, expand geographic reach, or secure critical reagent supply lines. Contract manufacturing and co-development agreements are increasingly common, enabling smaller innovators to scale while leveraging established quality systems. Firms that combine robust regulatory pathways, strong technical support, and flexible commercial terms are better positioned to capture long-term institutional contracts and to support multi-site deployments. Overall, the competitive landscape rewards companies that deliver end-to-end value-combining validated chemistry, reliable instruments, and responsive lifecycle services.

Actionable strategic moves for industry leaders to strengthen resilience, accelerate access, and create sustainable commercial differentiation in diagnostics

Industry leaders should prioritize a set of focused actions to navigate uncertainty and capture strategic opportunities. First, investing in manufacturing resilience and supplier diversification can reduce exposure to trade policy shocks and component shortages while supporting continuity for clinical customers. Second, strengthening regulatory and clinical evidence capabilities will accelerate market access in complex jurisdictions and provide payers with the data required for coverage decisions. Third, embedding digital capabilities into instruments and assays-ranging from connectivity and analytics to remote monitoring-can create recurring revenue streams and improve customer retention.

Moreover, companies should pursue targeted collaborations with healthcare providers and academic centers to generate real-world evidence and to refine product-market fit for specialized applications like oncology and genomics research. Commercial teams must also adapt contracting approaches to emphasize service-level agreements and outcome-based elements that resonate with procurement stakeholders. Finally, leaders should maintain agile scenario planning processes to respond quickly to policy shifts and supply chain disruptions, ensuring that operational and commercial tactics remain aligned with evolving market realities.

Comprehensive research methodology combining primary interviews, regulatory analysis, and value-chain mapping to ensure rigorous and validated findings

This analysis synthesizes primary and secondary research streams to deliver a comprehensive perspective on diagnostic substances. Primary inputs include structured interviews with laboratory directors, procurement executives, regulatory specialists, and product development leaders, providing frontline insights into adoption drivers, operational pain points, and procurement priorities. These qualitative inputs were triangulated with secondary sources such as peer-reviewed literature, regulatory guidance documents, and corporate filings to ensure factual rigor and contextual depth.

Analytical approaches included value-chain mapping to identify critical bottlenecks, scenario analysis to evaluate tariff- and supply-related risks, and comparative regional assessments to surface localization requirements. Attention was given to methodological transparency: stakeholders and data sources were chosen to reflect a balance of public and private sector perspectives, and assumptions underlying interpretive judgments are documented in the full report. Where applicable, findings were validated through peer review by subject-matter experts in molecular diagnostics, clinical laboratory operations, and health economics.

Final synthesis emphasizing alignment of technical excellence, regulatory compliance, and real-world utility as the decisive determinants of future success

Diagnostic substances are at the intersection of technological innovation and clinical necessity, and the sector's near-term trajectory will be governed by how well firms align product capabilities with real-world clinical and operational needs. Increasing emphasis on evidence of clinical utility, supply chain resilience, and regulatory adherence is raising the bar for new entrants while rewarding companies that can demonstrate end-to-end reliability. At the same time, digital enablement and integrated service models are creating new touchpoints for long-term customer engagement beyond transactional sales.

To succeed, stakeholders must balance investment in advanced platforms and reagent quality with pragmatic strategies for regional market access and procurement engagement. Proactive collaboration across manufacturers, clinical networks, and regulatory bodies will be essential to streamline adoption pathways and to capture the full potential of diagnostics for patient care and research advancement. Ultimately, organizations that can translate technical differentiation into measurable clinical outcomes and operational value will lead the next wave of growth and adoption in diagnostic substances.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in regulatory approvals for CRISPR-based diagnostic reagents in infectious disease testing
  • 5.2. Expansion of point-of-care molecular diagnostic platforms for antibiotic resistance detection
  • 5.3. Integration of AI-powered image analysis in immunohistochemistry diagnostics to improve cancer subtype classification
  • 5.4. Growing collaboration between diagnostic reagent suppliers and telemedicine platforms for remote sample analysis
  • 5.5. Adoption of next-generation sequencing assays in liquid biopsy diagnostics for early cancer detection
  • 5.6. Development of biodegradable microfluidic chips for eco friendly point-of-care diagnostic testing
  • 5.7. Increased utilization of multiplexed immunoassays targeting cytokine profiles in autoimmune disease monitoring
  • 5.8. Emergence of nanobody-based reagents enhancing sensitivity of in vitro diagnostic immunoassays
  • 5.9. Surging demand for companion diagnostics aligned with targeted oncology therapies in precision medicine

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diagnostic Substances Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Analyzers
    • 8.1.2. Imaging Equipment
    • 8.1.3. Molecular Diagnostic Instruments
      • 8.1.3.1. Next-Generation Sequencing
      • 8.1.3.2. PCR Machines
  • 8.2. Kits & Assays
    • 8.2.1. ELISA Kits
    • 8.2.2. Lateral Flow Assays
    • 8.2.3. PCR Kits
    • 8.2.4. Rapid Test Kits
  • 8.3. Reagents
    • 8.3.1. Antibody Reagents
    • 8.3.2. Antigen Reagents
    • 8.3.3. Enzymes
    • 8.3.4. Nucleic Acid Reagents
    • 8.3.5. Recombinant Proteins

9. Diagnostic Substances Market, by End-User

  • 9.1. Diagnostic Laboratories
  • 9.2. Forensic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Point-of-Care Testing Facilities
  • 9.5. Research & Academic Institutes

10. Diagnostic Substances Market, by Application

  • 10.1. Clinical Diagnostics
    • 10.1.1. Cardiology
    • 10.1.2. Endocrinology
    • 10.1.3. Infectious Diseases
    • 10.1.4. Neurology
    • 10.1.5. Oncology
  • 10.2. Forensic
    • 10.2.1. Blood Sample Testing
    • 10.2.2. DNA Analysis
    • 10.2.3. Toxicology
  • 10.3. Research
    • 10.3.1. Drug Discovery
    • 10.3.2. Genomics Research
    • 10.3.3. Proteomics Research

11. Diagnostic Substances Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Diagnostic Substances Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Diagnostic Substances Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Abbott Laboratories
    • 14.3.2. Agilent Technologies Inc.
    • 14.3.3. Asuragen, Inc. by Bio-Techne Corporation
    • 14.3.4. Becton, Dickinson and Company
    • 14.3.5. Bio-Rad Laboratories Inc.
    • 14.3.6. bioLytical Laboratories
    • 14.3.7. bioMerieux SA
    • 14.3.8. Cepheid by Danaher Corporation
    • 14.3.9. DiaSorin S.p.A.
    • 14.3.10. Enzo Biochem, Inc.
    • 14.3.11. Hitachi Ltd.
    • 14.3.12. Hoffmann-La Roche AG
    • 14.3.13. Hologic Inc.
    • 14.3.14. HyTest Ltd.
    • 14.3.15. Illumina Inc.
    • 14.3.16. Merck KGaA
    • 14.3.17. OraSure Technologies, Inc.
    • 14.3.18. Ortho Clinical Diagnostics
    • 14.3.19. Qiagen N.V.
    • 14.3.20. Quidel Corporation
    • 14.3.21. Randox Laboratories Ltd.
    • 14.3.22. Sekisui Diagnostics, LLC
    • 14.3.23. Siemens AG
    • 14.3.24. Sysmex Corporation by TOA Corporation
    • 14.3.25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. DIAGNOSTIC SUBSTANCES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. DIAGNOSTIC SUBSTANCES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DIAGNOSTIC SUBSTANCES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBST